PROCEPT BioRobotics (PRCT)
(Delayed Data from NSDQ)
$57.38 USD
-4.62 (-7.45%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $57.45 +0.07 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PRCT 57.38 -4.62(-7.45%)
Will PRCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PRCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRCT
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Tops Revenue Estimates
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
PRCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
Other News for PRCT
Strong Buy Rating for PROCEPT BioRobotics Amidst Surging Q2 Performance and Market Adoption
PROCEPT BioRobotics Corp (PRCT) Q2 2024 Earnings Call Transcript Highlights: Record Revenue ...
PROCEPT BioRobotics (PRCT) Receives a Buy from Truist Financial
Strong Growth and Robust Performance Justify Buy Rating for PROCEPT BioRobotics
Piper Sandler Issues a Buy Rating on PROCEPT BioRobotics (PRCT)